Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gene research yields new prostate cancer testing method

Gene research yields new prostate cancer testing method

12th September 2013

US researchers have developed a new means of gauging the aggressiveness of prostate cancer by assessing a new biomarker.

A team from the Columbia University Medical Center have identified three genes – FGFR1, PMP22 and CDKN1A – that between them can accurately predict the outcome of seemingly low-risk tumours.

A blinded retrospective study, the researchers evaluated the accuracy of the three-gene panel on initial biopsy specimens from 43 patients, with the test accurately identifying all 14 of the subjects who ultimately went on to develop advanced prostate cancer.

The researchers now plan to evaluate the test in a larger prospective clinical trial.

Study leader Dr Cory Abate-Shen, a professor of urological oncology at the Columbia University Medical Center, said: "The three-gene biomarker could take much of the guesswork out of the diagnostic process and ensure that patients are neither overtreated nor undertreated."

Prostate cancer is the most common cancer in men in the UK, with more than 40,000 new cases being diagnosed every year.ADNFCR-8000103-ID-801636821-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.